New data suggest investigational osteoarthritis drug may have promising senotherapeutic effect
AKL’s investigational oral osteoarthritis drug APPA may have a dual effect on senescence with potential in other diseases of aging.
Most Popular
Solving the Alzheimer’s disease puzzle – one piece at a time
Researchers have uncovered a novel regulatory mechanism in the brain, the malfunctioning of which may contribute to Alzheimer's.
New technique for studying mitochondria could enhance neurodegenerative imaging
Advance offers a new way of investigating diseases – including Alzheimer's and Parkinson's – where mitochondria are disrupted.
Previously unknown cell mechanism could help counter aging
Unknown mechanism of how cells ‘remember’ their identity when they divide – the cells’ so-called epigenetic memory – discovered.
£4m Longitude Prize on Dementia bags 175 entries
Innovations from around the world, including smart glasses and gaming software, aim to help dementia sufferers regain independence.
Supplements
Health organisations petition FDA to reverse its position on NMN supplements
ANH and NPA ask the Food and Drug Administration to reverse its position and not exclude NMN from dietary supplement definition.
Editor's pick
New data suggest investigational osteoarthritis drug may have promising senotherapeutic effect
AKL’s investigational oral osteoarthritis drug APPA may have a dual effect on senescence with potential in other diseases of aging.
TruDiagnostic and NADMED partner on new NAD blood diagnostic
Using novel TruDiagnostic/NADMED test, US healthcare providers can test patients' NAD+ levels at home or in the clinic.
Longevity investment bulletin: Celmatix, BlueRock, TruDiagnostic and more
Longevity investment bulletin, featuring Celmatix, TruDiagnostic, BlueRock, Cyclarity, Retro Bio, Mitrix and Cambrian.
Retro: A longevity biotech triple-threat?
Joe Betts-LaCroix on investing in longevity biotech and Retro’s progress in cellular reprogramming, autophagy, and plasma programs.
Watch now
Cyclarity: When bad guy cells have a change of heart
How Cyclarity is targeting atherosclerosis and giving the body the means to reverse disease from the inside out.
£4m Longitude Prize on Dementia bags 175 entries
Innovations from around the world, including smart glasses and gaming software, aim to help dementia sufferers regain independence.
Longitude Prize on dementia names expert judging panel
Turing Institute, University of Cambridge and US longevity experts named judges of ground-breaking dementia tech prize.
Five key steps to getting an AgeTech startup funded
Partner at venture capital firm Flint Capital reveals five key steps to funding success for AgeTech startups.
Aging in place is the “holy grail” of AgeTech
Keren Etkin, author of The AgeTech Revolution, talks aging in place and agetech and how they can benefit society at large.
